daclatasvir

Known as: DCV 
An orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
UNLABELLED Chronic hepatitis C virus (HCV) infection with advanced cirrhosis or post-liver transplantation recurrence represents… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 4
Is this relevant?
Highly Cited
2016
Highly Cited
2016
UNLABELLED Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanced liver disease, are a… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
UNLABELLED Treatment options for patients with hepatitis C virus (HCV) genotype 3 infection are limited, with the currently… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND The combination of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and the NS5B inhibitor sofosbuvir has shown… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
UNLABELLED All-oral combinations of direct-acting antivirals may improve efficacy and safety outcomes for patients with hepatitis… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND An unmet need exists for interferon-free and ribavirin-free treatments for chronic hepatitis C virus (HCV) infection… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
The nonstructural 5A (NS5A) protein is a target for drug development against hepatitis C virus (HCV). Interestingly, the NS5A… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
UNLABELLED Patients with chronic hepatitis C virus (HCV) infection and previous null response to pegylated interferon (Peg-IFN… (More)
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Most organisms have evolved defense mechanisms to protect themselves from viruses and other pathogens. Arthropods lack the… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?